Miruvor
Sign up
The short answer

What studies of moclobemide found

11papers on moclobemide
92people in 2 studies testing moclobemide alone
1randomised trial, the strongest kind of study

At a glance, by condition

ME/CFS: C Might help, very uncertain

Based on the strongest evidence, studies with no comparison group (very low certainty): 4 findings, all C.

4 outcomes rated · see each below

How we got this

Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.

What this means: Moclobemide might help some people with ME/CFS, but research can’t show it yet. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.

Ask about this treatment

Sign up free to read the rest of what studies found.

You’ll see the full picture: how each symptom fared, every grade with its reasons, side effects, the doses studied and all 11 papers.

The grades, in plain words

Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.

  1. A
    HelpsImprovement, high certainty
    Probably helpsImprovement, moderate certainty
  2. B
    May helpImprovement, low certainty
  3. Moclobemide · ME/CFS is hereC
    Might help, very uncertainImprovement, very low certainty
    Mixed resultsStudies disagree
  4. D
    Little or no differenceStudies found little or no difference
  5. F
    HarmsIt made things worse

By symptom and daily life

ME/CFS

Symptoms

Fatigue2 studies · 92 people took moclobemide Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); not all results were tested against chance.

Studies with no comparison group2 studies · 92 people with results

Fatigue improved.

The evidence is very uncertain about the effect of moclobemide on fatigue in ME/CFS. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Not all results were tested against chance
See the 2 studies
  1. An open study of the efficacy and adverse effects of moclobemide in patients with the chronic fatigue syndrome. (1997)

    People in the study
    49 in the study · 45 with outcome data
    Dose
    up to 600 mg a day
    Outcome
    Fatigue Chalder fatigue scale
    Effect
    better (not tested)
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
  2. A randomized, double-blind placebo-controlled trial of moclobemide in patients with chronic fatigue syndrome. (2000)

    People in the study
    90 randomised
    Dose
    450 to 600 mg/day
    Outcome
    subjective energy
    Effect
    better (not tested)
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Depression1 study · 45 people took moclobemide Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (45 in all).

Studies with no comparison group49 in the study · 45 with outcome data · 6 weeks · up to 600 mg a day

Depression improved.

The evidence is very uncertain about the effect of moclobemide on depression in ME/CFS. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (45 in all)
See the 1 study
  1. An open study of the efficacy and adverse effects of moclobemide in patients with the chronic fatigue syndrome. (1997)

    People in the study
    49 in the study · 45 with outcome data
    Dose
    up to 600 mg a day
    Outcome
    HAD depression score
    Effect
    better
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Low mood or anxiety1 study · 45 people took moclobemide Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (45 in all); not all results were tested against chance.

Studies with no comparison group49 in the study · 45 with outcome data · 6 weeks · up to 600 mg a day

Low mood or anxiety improved.

The evidence is very uncertain about the effect of moclobemide on low mood or anxiety in ME/CFS. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (45 in all)
  • Not all results were tested against chance
See the 1 study
  1. An open study of the efficacy and adverse effects of moclobemide in patients with the chronic fatigue syndrome. (1997)

    People in the study
    49 in the study · 45 with outcome data
    Dose
    up to 600 mg a day
    Outcome
    HAD depression Hospital Anxiety and Depression
    Effect
    better (not tested)
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I

Daily life and health overall

Overall symptoms1 study · 45 people took moclobemide Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (45 in all); not all results were tested against chance.

Studies with no comparison group49 in the study · 45 with outcome data · 6 weeks · up to 600 mg a day

Overall symptoms improved.

The evidence is very uncertain about the effect of moclobemide on overall symptoms in ME/CFS. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (45 in all)
  • Not all results were tested against chance
See the 1 study
  1. An open study of the efficacy and adverse effects of moclobemide in patients with the chronic fatigue syndrome. (1997)

    People in the study
    49 in the study · 45 with outcome data
    Dose
    up to 600 mg a day
    Outcome
    Clinical Global Impression (CGI) change scale Clinical Global Impression
    Effect
    better (not tested)
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I

Side effects

Side effects studies reported5 kinds
Side effects studies reported, and how many studies reported each
Side effectStudies that reported it
Anxiety or irritability1 study
Fatigue1 study
Headache1 study
Nausea or stomach upset1 study
Trouble sleeping1 study

Doses studied

What researchers used, as the papers print it; not a recommendation.

  1. 1Start

    450 to 600 mg at the start

  2. 2Raise

    Raised step by step in 2 of 2 studies

  3. 3Top dose

    Most often 600 mg (2 of 2 studies)

Doses across 2 studies

450 to 600 mg.

Each study’s dose, as printed

All papers

  1. A randomized, double-blind placebo-controlled trial of moclobemide in patients with chronic fatigue syndrome.2000 · placebo trial · 90 randomised
    Summary

    This randomized, placebo-controlled, double-blind trial enrolled 90 patients with chronic fatigue syndrome, diagnosed with the authors’ system that approximates CDC criteria. Participants received moclobemide 450 to 600 mg/day or placebo; the duration of treatment was not reported. The abstract reports that 51% (24/47) of patients receiving moclobemide improved compared with 33% (14/43) of patients receiving placebo (odds ratio = 2.16, 95% confidence interval [CI] = 0.9 to 5.1). Drug response was best characterized symptomatically by an increase in the subjective sense of vigor and energy rather than a reduction in depressed mood. The effect of moclobemide on subjective energy was detectable within the first 2 weeks of treatment and increased across the course of the study. The greatest reduction in clinician-rated disability was in patients with concurrent immunologic dysfunction (mean difference in standardized units of improvement = 0.8, 95% CI = 0.03 to 1.6). Side effects and withdrawals were not reported in the abstract. The authors conclude that moclobemide produces some improvement in key symptoms experienced by patients with chronic fatigue syndrome, that this effect is not dependent on the presence of concurrent psychological distress, and that it is likely to be shared with other monoamine oxidase inhibitors. Limitations are not stated in the abstract.

  2. An open study of the efficacy and adverse effects of moclobemide in patients with the chronic fatigue syndrome.1997 · no comparison group · 49 in the study · 45 with outcome data
    Summary

    This open study asked whether moclobemide was well tolerated and influenced chronic fatigue syndrome, including in people with co-morbid major depressive illness and with sleep disturbance. Forty-nine patients with chronic fatigue syndrome were recruited from a fatigue clinic at St Bartholomew's hospital. Patients were given moclobemide up to 600 mg a day for 6 weeks, with no placebo group. The primary measure was the self-rated Clinical Global Impression change scale; secondary measures included fatigue, HAD depression, anxiety, somatic amplification and sleep. After 4 weeks, 11 out of 45 (24%) rated themselves much or very much better. By week 6, seven out of 14 (50%) of the depressed individuals rated themselves better, compared with six out of 31 (19%) of those who were not depressed (31% difference, 95% CI 1-60; Fisher's exact test p=0.04). There was no significant difference in reduction of fatigue between categories (median reductions of 5 versus 3 points), and sleep disturbance made no difference to outcome at any time. Four (8%) patients dropped out, three because of adverse effects; three dropped out within the first 2 weeks complaining of increased anxiety. The most frequent adverse effects were reported at onset by 42 per cent of individuals; adverse effects were otherwise mild and transient. The authors state the study lacked a placebo treatment and had small groups.

  3. Bupropion augmentation in the treatment of chronic fatigue syndrome with coexistent major depression episode.2006 · case report · 1 in the study
    Summary

    This case report described one 39-year-old woman with chronic fatigue syndrome and a coexistent major depression episode, admitted to a psychiatric setting. She was given paroxetine 20 mg/day increased to 40 mg/day, and bupropion was added and gradually increased to 450 mg/day; treatment reached full remission after 6 weeks. There was no comparison group. Symptoms, BDI, MADRS and HAM-D were assessed. After 3 weeks, symptoms improved markedly, reaching full remission after 6 weeks; BDI was 22 at baseline and 5 after 6 weeks, MADRS was 25 and 6, and HAM-D was 22 and 6. On follow-up 6 and 12 months later, symptoms were still absent and she could enter a part time job. After an initial boost of energy, she deteriorated slightly. The authors stated that the report is a case and that controlled studies in larger CFS samples are warranted.

  4. A Systematic Review of Drug Therapies for Chronic Fatigue Syndrome/Myalgic Encephalomyelitis.2016 · systematic review
    Summary

    This systematic review examined drug therapies for chronic fatigue syndrome or myalgic encephalomyelitis (CFS/ME). Ovid MEDLINE, EMBASE, and PubMed were searched from the beginning of their archives to March 2016. The review included 26 randomized, placebo-controlled trials that met its criteria; these trials tested 20 drug therapies. The review reports effectiveness by categories from not effective to highly effective and says no universal pharmaceutical treatment can be recommended. Hydrocortisone findings were conflicting: across studies it was reported as mildly effective, slightly effective, not effective, and moderately effective; in one study the well-being improvement was not significant, and Blockmans et al found no clinical improvement. Rituximab was reported to produce a significant and lasting improvement, but the review states it is premature to conclude a lasting improvement in primary assessed domains; primary end points were evaluated for 3 months and secondary end points up to 12 months. For intravenous immunoglobulin, Rowe reported headache, fatigue, and difficulty concentrating significantly worse in the intervention group after the first infusion, with no differences after the third and final infusion. The review states no pharmaceutical therapy resulted in severe adverse events. It notes nefazodone was discontinued in 2004 after patients developed hepatic and visual disorders. Forsyth et al and Young each had N = 26; Young lacked male participants in the intervention cohort. The authors state that no clear recommended pharmaceutical therapy for CFS/ME exists and call for standardized diagnostic criteria and outcome measurements.

  5. Interventions for the treatment, management and rehabilitation of patients with chronic fatigue syndrome/myalgic encephalomyelitis: an updated systematic review.2006 · systematic review
    Summary

    This updated systematic review asked whether any intervention is effective for treatment, management or rehabilitation of adults and children with CFS/ME. The authors searched eleven electronic databases and included 70 studies, of which 59 were RCTs; comparisons were between treatment and control groups. Interventions included CBT, GET, rehabilitation, immunological and pharmacological treatments, supplements and complementary therapies. Outcomes covered physical, psychological, laboratory/physiological and quality-of-life measures. CBT and GET appeared to reduce symptoms and improve function based on RCTs. In a CBT trial (n=69), physical functioning, fatigue and symptoms favoured CBT (P<0.003) and school attendance favoured treatment (P=0.04). Another CBT trial (n=65) found no significant difference for fatigue, anxiety and depression, or disability. In GET trials, CGI and fatigue favoured treatment (n=49; P<0.03), and fatigue and depression/anxiety were significantly better (n=61; P=0.027). One GET trial reported withdrawal of one patient in each group because of worsening symptoms; eleven patients withdrew because of adverse events in a GET with or without fluoxetine trial. Galantamine (n=434) showed no significant differences; 130 patients withdrew, 389 reported adverse events and 88 withdrew. Acetyl-L-carnitine and propionyl-L-carnitine (n=90) improved general fatigue in PLC (P=0.004) and combined group (P<0.001), and mental fatigue in ALC group (P=0.015); 8 patients withdrew due to side effects. Staphylococcus toxoid (n=98) had 13 treatment-group and 7 placebo-group patients with side effects. Hydrocortisone/fludrocortisone (n=80) found no significant differences.

  6. Interventions for the treatment and management of chronic fatigue syndrome: a systematic review.2001 · systematic review
    Summary

    This systematic review asked whether interventions for chronic fatigue syndrome (CFS) work. Nineteen specialist databases were searched, and 44 trials met inclusion criteria: 36 randomized controlled trials and 8 controlled trials. Treatments were grouped by type and compared with control conditions. Outcomes were classified as positive, negative, or no effect. Three randomized controlled trials of GET all showed an overall beneficial effect compared with control groups. Three of four randomized controlled trials of CBT found a positive overall effect; one controlled trial did not find overall beneficial effects. One randomized controlled trial found no effect of fluoxetine either alone or with GET. Hydrocortisone showed an overall beneficial effect in one randomized controlled trial and some beneficial effects in another. For immunoglobulin, two randomized controlled trials showed an overall beneficial effect, two showed some positive effects, and the largest reported no effect. Acyclovir showed a negative effect for one outcome. Randomized controlled trials of fludrocortisone, antidepressants, moclobemide, sulbutiamine, growth hormone and galanthamine hydrobromide found no effects. Oral NADH showed an overall beneficial effect in one randomized controlled trial. Harms included withdrawals from immunoglobulin therapy (2 due to severe constitutional symptoms, 1 due to a skin eruption, 1 due to mild but transient liver failure, 1 due to phlebitis, and 2 whose adverse effects were not reported), 3 withdrawals from acyclovir due to reversible renal failure, and 2 participants leaving the magnesium group after a generalized rash. CBT trials had a dropout rate of 19% (114/589), GET trials 18% (68/370), and pharmacological trials 11% (99/869).

  7. Treating chronic fatigue syndrome - a study into the scientific evidence for pharmacological treatments.2011 · review
    Summary

    The paper reports a questionnaire survey of 94 CFS patients from Queensland and New South Wales, recruited through support groups and newspaper and email advertisements, plus a search for randomised controlled trials. Patients filled out a questionnaire on current medicines and supplements; no treatment was given by the authors, and the survey had no comparison group. The 94 patients used 474 different medicines and supplements. Commonly used were antidepressants (41%), sedatives (27%), B vitamins (47%), magnesium (24%) and co-enzyme Q10 (7%). The search identified 20 RCTs. Findings included no difference for fluoxetine on fatigue or SF-36, no difference between treatment and placebo on individual questionnaires, and no effect for several agents including phenelzine, moclobemide, valaciclovir, terfenadine, melatonin, ginseng, bovine liver extract and a polynutrient supplement. One hydrocortisone trial reported 87% rated themselves improved versus 17% on placebo (p<0.001); another reported 53% vs. 29% (p=0.04) improvement in wellness score. Harm notes included diarrhoea with high-dose oral magnesium, long-term adrenal gland suppression with adrenal hormones, addiction and loss of effectiveness with benzodiazepines and opiates, and hormonal/lipid changes with DHEA. No worsening or stopping was reported. The authors state limitations.

  8. Pharmacological treatment of chronic fatigue syndrome: focusing on the role of antidepressants.2009 · review
    Summary

    This review did not run its own trial; it summarized published data on pharmacological treatment of chronic fatigue syndrome (CFS), identified through a PubMed literature search. The review covers antidepressants and other psychotropic agents in CFS. In included randomized, placebo-controlled trials, moclobemide vs. placebo (47 vs. 43) showed clinically global improvement 51 vs. 33% (OR = 2.16); KPI mean difference between two groups was 0.28 favoring MCB, and Vigor subscale on POMS mean difference was 0.51 favoring MCB. Overall response by subjective global impression was 51% with moclobemide vs. 23% with placebo. At 12 weeks, MIR failed to separate from PBO on FS; at 24 weeks, CBT + MIR showed significantly more reduction in FS scores than PBO + CBT, with an observed difference of 5.5 (95% CI = 15.4 – 22), whereas MIR + CBT failed to separate from PBO + CBT. Fluoxetine failed to separate from PBO on SFS and BDI scores, and failed to demonstrate benefit on listed outcome measures. The review lists harms: TCAs potentially induce sedation and orthostatic hypotension; MAOIs have hypertensive crisis; stimulant medications carry risks of misuse, abuse, withdrawal, and diversion. Authors state research does not support definitive conclusions about antidepressant efficacy in CFS.

  9. Antidepressants and cognitive-behavioral therapy for symptom syndromes.2006 · review
    Summary

    This review article examined antidepressant medications and cognitive-behavioral therapy for 11 somatic syndromes, including chronic fatigue syndrome. It did not report its own enrolments, analysed patients, setting, or follow-up; patient counts were not reported. The review described trials of antidepressants versus placebo and trials of CBT. Outcomes included global symptoms, pain, sleep, fatigue, mood, and energy. For CFS, the review reports that a systematic review found two interventions beneficial for improving but not curing symptoms: CBT and graded exercise. It reports that six of the seven RCTs of CBT on CFS found benefit, with an effect lasting for 5 years. Among antidepressant trials, two fluoxetine trials showed no benefit other than for depressive symptoms; one phenelzine trial showed improvement in multiple CFS symptoms, illness severity, and mood; and a moclobemide trial showed improvement in subjective vigor and energy. The review reports mixed evidence that antidepressants lead to overall improvement and states there is no randomized trial evidence demonstrating any efficacy for methylphenidate. The authors state that evidence for antidepressants in CFS is limited and insufficient for convincing conclusions.

A little hope, every Sunday

New recovery stories and data-driven research on ME/CFS and long COVID. Ideas worth considering, and the evidence behind them.

Free · Unsubscribe anytime